Trial Profile
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor: The SWAP (SWitching Anti Platelet)-3 Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Prasugrel
- Indications Acute coronary syndromes; Thrombosis
- Focus Pharmacodynamics
- Acronyms SWAP-3
- 12 Nov 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 04 Mar 2014 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
- 14 Jan 2014 New trial record